公开(公告)号：WO1996012807A2

公开(公告)日：1996-05-02

申请号：PCT/US1995013703

申请日：1995-10-23

Applicant: GENELABS TECHNOLOGIES, INC.

Inventor： GENELABS TECHNOLOGIES, INC. ,  FUERST, Thomas, R. ,  McATEE, C., Patrick ,  YARBOUGH, Patrice, O. ,  ZHANG, Yi-Fan

IPC: C12N15/40

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C07K16/10 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/61 ,  C12N2710/14143 ,  C12N2770/28122 ,  C12N2770/28123 ,  C12Q1/707 ,  G01N33/5767

Abstract: Antigens are provided which are derived from the enterically transmitted non-A/non-B viral hepatitis agent, known as hepatitis E virus (HEV). The HEV antigens and in particular, soluble species of the capsid protein encoded by the carboxy terminal region of HEV ORF2, are immunoreactive with sera from individuals infected with HEV. In one embodiment, these antigens may be produced by a baculovirus expression vector and form virus-like particles (VLPs). The antigens are useful as diagnostic reagents in diagnostic methods and kits for determining infection of an individual with HEV. The antigens are also useful in vaccine compositions effective in methods for preventing HEV infection.

Abstract translation: 提供抗原，其来源于被称为戊型肝炎病毒（HEV）的肠道传播的非A /非B型病毒性肝炎病毒。 特别是由HEV ORF2的羧基末端区编码的衣壳蛋白的可溶性物质与来自感染HEV的个体的血清具有免疫反应性。 在一个实施方案中，这些抗原可以由杆状病毒表达载体产生并形成病毒样颗粒（VLP）。 抗原在诊断方法和试剂盒中用作确定HEV感染个体的诊断试剂。 抗原也可用于有效预防HEV感染的方法的疫苗组合物中。